Literature DB >> 19090788

Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease.

Mamoru Satoh1, Yoshitaka Minami, Yuji Takahashi, Tsuyoshi Tabuchi, Tomonori Itoh, Motoyuki Nakamura.   

Abstract

Telomere erosion of EPCs (endothelial progenitor cells) may be a key factor in endothelial cell senescence and is highly dependent on cellular oxidative damage. The aim of the present study was to investigate whether LLT (lipid-lowering therapy) with statins could attenuate EPC telomere erosion in patients with CAD (coronary artery disease). The study included 100 patients with stable CAD and 25 subjects without CAD as controls. CAD patients were randomized to 12 months of intensive LLT with atorvastatin or moderate LLT with pravastatin. EPCs were obtained from peripheral blood at baseline and after 12 months of statin therapy. Telomere length in EPCs was measured by FISH (fluorescence in situ hybridization) and oxidative DNA damage by flow cytometry of oxidized DNA bases. EPC telomere length was shorter in the CAD group than in the controls, and oxidative DNA damage to EPCs was higher in the CAD group compared with controls. After 12 months of therapy, changes in lipid profiles were greater in the intensive LLT group than in the moderate LLT group. Intensive LLT markedly increased EPC number and decreased oxidative DNA damage in EPCs (both P<0.05), with no change in telomere length. In contrast, moderate LLT did not change EPC counts or oxidative DNA damage, but showed telomere shortening (P<0.05). There was a weak negative correlation between changes in EPC number and LDL (low-density lipoprotein)-cholesterol levels after intensive LLT, whereas there was no correlation between them after moderate LLT. With in vitro culturing of EPCs subjected to oxidative stress, atorvastatin led to the prevention of EPC telomere shortening compared with pravastatin. In conclusion, the present study has demonstrated that intensive LLT may prevent EPC telomere erosion in patients with CAD, possibly contributing to the beneficial effects of intensive LLT in this disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19090788     DOI: 10.1042/CS20080404

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  19 in total

Review 1.  Genetic and epigenetic trends in telomere research: a novel way in immunoepigenetics.

Authors:  Dora Melicher; Edit I Buzas; Andras Falus
Journal:  Cell Mol Life Sci       Date:  2015-07-20       Impact factor: 9.261

Review 2.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

3.  Impact of prior chronic statin therapy and high-intensity statin therapy at discharge on circulating endothelial progenitor cell levels in patients with acute myocardial infarction: a prospective observational study.

Authors:  Natália António; Rosa Fernandes; Ana Soares; Francisco Soares; Ana Lopes; Tiago Carvalheiro; Artur Paiva; Guilherme Mariano Pêgo; Luís A Providência; Lino Gonçalves; Carlos Fontes Ribeiro
Journal:  Eur J Clin Pharmacol       Date:  2014-07-22       Impact factor: 2.953

4.  Telomere biology in cardiovascular disease - role of insulin sensitivity in diabetic hearts.

Authors:  Naoki Makino; Makoto Sasaki; Toyoki Maeda; Kosi Mimori
Journal:  Exp Clin Cardiol       Date:  2010

5.  Statins impair survival of primary human mesenchymal progenitor cells via mevalonate depletion, NF-κB signaling, and Bnip3.

Authors:  Yun Li; Alison L Müller; Melanie A Ngo; Kiranjit Sran; Daniel Bellan; Rakesh C Arora; Lorrie A Kirshenbaum; Darren H Freed
Journal:  J Cardiovasc Transl Res       Date:  2014-12-30       Impact factor: 4.132

Review 6.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 7.  Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs.

Authors:  Natália António; Rosa Fernandes; Noela Rodriguez-Losada; Manuel F Jiménez-Navarro; Artur Paiva; Eduardo de Teresa Galván; Lino Gonçalves; Carlos Fontes Ribeiro; Luís A Providência
Journal:  Eur J Clin Pharmacol       Date:  2009-12-10       Impact factor: 2.953

8.  Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease.

Authors:  Ramin Farzaneh-Far; Jue Lin; Elissa S Epel; William S Harris; Elizabeth H Blackburn; Mary A Whooley
Journal:  JAMA       Date:  2010-01-20       Impact factor: 56.272

9.  Telomere Shortening, Regenerative Capacity, and Cardiovascular Outcomes.

Authors:  Muhammad Hammadah; Ibhar Al Mheid; Kobina Wilmot; Ronnie Ramadan; Naser Abdelhadi; Ayman Alkhoder; Malik Obideen; Pratik M Pimple; Oleksiy Levantsevych; Heval M Kelli; Amit Shah; Yan V Sun; Brad Pearce; Michael Kutner; Qi Long; Laura Ward; Yi-An Ko; Kareem Hosny Mohammed; Jue Lin; Jinying Zhao; J Douglas Bremner; Jinhee Kim; Edmund K Waller; Paolo Raggi; David Sheps; Arshed A Quyyumi; Viola Vaccarino
Journal:  Circ Res       Date:  2016-12-12       Impact factor: 17.367

Review 10.  Circulating endothelial progenitor cells: a new approach to anti-aging medicine?

Authors:  Nina A Mikirova; James A Jackson; Ron Hunninghake; Julian Kenyon; Kyle W H Chan; Cathy A Swindlehurst; Boris Minev; Amit N Patel; Michael P Murphy; Leonard Smith; Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan
Journal:  J Transl Med       Date:  2009-12-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.